Staff Profile

I am a Prostate Cancer UK fellow at the Newcastle University Centre for Cancer. My group is focussed on the mechanisms of glyco-immune suppression in prostate cancer. I am interested in understanding how Siglec immunoreceptors shape macrophage and neutrophil phenotype in the tumour immune microenvironment and how this contributes to immunotherapy resistance. We are working to develop new therapies to target sialoglycan-Siglec signalling and to understand how this will fit with current standard-of-care therapies.

For a full list of publications see Google Scholar: here

Education and training

Prostate Cancer UK Fellow - Biosciences Institute, Newcastle University

Research Associate. Glycans as therapeutic targets and biomarkers for prostate cancer - Institute of Genetic Medicine, Newcastle University

Ph.D. in Non-alcoholic fatty liver disease and hepatocellular carcinoma - Institute of Cellular Medicine, Newcastle University

MBiolSci. Genetics - University of Liverpool

Targeting the sialoglycan-Siglec axis in prostate cancer

1. Understanding how Siglec ligands (sialic acid containing glycans) change during prostate cancer pathogenesis and how they are affected by common prostate cancer treatments
2. Investigating how Siglec receptors modulate myeloid cell phenotype and how this then contributes to immunotherapy resistance
3. Developing new therapies to target sialoglycan-Siglec interactions and understanding how these can be used to treat prostate cancer

Undergraduate seminar lead

Undergraduate practical lead

I regularly supervise Undergraduate and MRes project students in the lab. 

PhD Supervision:

Primary supervisor

Rebecca Garnham 2020-2024

Co-supervisor

Kayla Bastian 2019 - 2023

Emily Archer-Goode 2020-2024

• Articles

  • Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, Marques FJG, Pye H, Yo EC, Islam K, Oo HZ, McClurg UL, Wilson L, Thomas H, Frame FM, Orozco-Moreno M, Bastian K, Arredondo HM, Roustan C, Gray MA, Kelly L, Tolson A, Mellor E, Hysenaj G, Goode EA, Garnham R, Duxfield A, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Bogdan D, Westaby D, Fowler G, Flohr P, Yuan W, Sharp A, de Bono J, Maitland NJ, Wisnovsky S, Bertozzi CR, Heer R, Guerrero RH, Daugaard M, Leivo J, Whitaker H, Pitteri S, Wang N, Elliott DJ, Schumann B, Munkley J. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene 2023, 42, 926–937.
  • Hodgson K, Orozco-Moreno M, Scott E, Garnham R, Livermore K, Thomas H, Zhou Y, He J, Bermudez A, Garcia Marques FJ, Bastian K, Hysenaj G, Archer Goode E, Heer R, Pitteri S, Wang N, Elliott DJ, Munkley J. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer. Scientific Reports 2023, 13(1), 17031.
  • Scott E, Archer Goode E, Garnham R, Hodgson K, Orozco-Moreno M, Turner H, Livermore K, Putri Nangkana K, Frame FM, Bermudez A, Garcia Marques FJ, McClurg UL, Wilson L, Thomas H, Buskin A, Hepburn A, Duxfield A, Bastian K, Pye H, Arredondo HM, Hysenaj G, Heavey S, Stopka-Farooqui U, Haider A, Freeman A, Singh S, Johnston EW, Punwani S, Knight B, McCullagh P, McGrath J, Crundwell M, Harries L, Heer R, Maitland NJ, Whitaker H, Pitteri S, Troyer DA, Wang N, Elliott DJ, Drake RR, Munkley J. ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression. Journal of Pathology 2023, 261(1), 71-84.
  • Garnham R, Geh D, Nelson R, Ramon-Gil E, Wilson L, Schmidt EN, Walker L, Adamson B, Buskin A, Hepburn A, Hodgson K, Kendall H, Frame FM, Maitland NM, Coffey K, Robson CN, Elliott DJ, Heer R, Macauley MS, Munkley J, Gaughan L, Leslie J, Scott E. ST3Gal1 synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. bioRxiv 2023.
  • Alebady ZAH, Azizyan M, Nakjang S, Lishman-Walker E, Al-Kharaif D, Walker S, Choo HX, Garnham R, Scott E, Johnson KL, Robson CN, Coffey K. CDC20 is regulated by the histone methyltransferase, KMT5A, in castration resistant prostate cancer. Cancers 2023, 15(14), 3597.
  • Scott E, Garnham R, Cheung K, Duxfield A, Elliott DJ, Munkley J. Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer. International Journal of Molecular Sciences 2022, 23(15), 8184.
  • Hall Z, Chiarugi D, Charidemou E, Leslie J, Scott E, Pelligrinet L, Allison M, Mocciaro G, Anstee QM, Evan GI, Hoare M, VidalPuig A, Oakley F, Vacca M, Griffin JL. Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma . Hepatology 2021, 73(3), 1028-1044.
  • Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, Oo HZ, Maia TM, Cheung K, Ehrmann I, Livermore KE, Zielinska H, Thompson O, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Daugaard M, Cockell S, Barbosa-Morais NL, Oltean S, Elliott DJ. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. eLife 2019, 8, e47678.
  • Govaere O, Petz M, Wouters J, Vandewynckel Y-P, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 2017, 36, 6605-6616.
  • Luukkonen PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, Hyotylainen T, Ali A, Juuti A, Leivonen M, Tukiainen T, Ahonen L, Scott E, Palmer JM, Arola J, Orho-Melander M, Vikman P, Anstee QM, Olkkonen VM, Oresic M, Groop L, Yki-Jarvinen H. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. Journal of Hepatology 2017, 67(1), 128-136.

• Reviews

  • Advani R, Luzzi S, Scott E, Dalgliesh C, Weischenfeldt J, Munkley J, Elliott DJ. Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer. Oncogene 2023, 42, 3161–3168.
  • Buskin A, Scott E, Nelson R, Gaughan L, Robson CN, Heer R, Hepburn AC. Engineering prostate cancer in vitro: what does it take?. Oncogene 2023, 42, 2417–2427.
  • Scott E, Elliott DJ, Munkley J. Tumour associated glycans: A route to boost immunotherapy?. Clinica Chimica Acta 2020, 502, 167-173.
  • Munkley J, Scott E. Targeting Aberrant Sialylation to Treat Cancer. Medicines 2019, 6(4), 102.
  • Garnham R, Scott E, Livermore KE, Munkley J. ST6GAL1: A key player in cancer (Review). Oncology Letters 2019, 18(2), 983-989.
  • Scott E, Munkley J. Glycans as Biomarkers in Prostate Cancer. International Journal of Molecular Sciences 2019, 20(6), 1389.